Polaryx Therapeutics (PLYX) Free Cash Flow (2025 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Free Cash Flow of -$2.1 million for Q1 2026, down 190.97% year-over-year from $2.3 million in Q1 2025, and down 190.97% quarter-over-quarter from -$709000.0 in Q1 2025.
Polaryx Therapeutics (PLYX) Free Cash Flow (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Free Cash Flow for 2 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 190.97% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$2.8 million (changed N/A YoY), while the FY2025 annual figure was -$3.9 million, down 53.28% from the prior year.
- Free Cash Flow eased to -$2.1 million in Q1 2026 per PLYX's latest filing, from -$709000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at -$709000.0 in Q1 2025 and bottomed at -$2.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Polaryx Therapeutics | 99.45 Mn | 87.91 Mn | - | -1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 Mn |
| Jun 30, 2026 | -1.33 Mn |
| Mar 31, 2026 | -2.06 Mn |
| Mar 31, 2026 | -2.06 Mn |
| Mar 31, 2025 | -709,000.00 |
| Mar 31, 2025 | -709,000.00 |